PFIZERNSEPfizer Limited· Pharmaceuticals & BiotechnologyHighNeutral
Announced Mon, 9 Feb, 2026 · 19:29 IST

Pfizer Q3 FY26 PAT up 11% to 142 cr; revenue grows about 20% to 645 cr

PFIZER · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
+3.7%Reaction day
₹4770.00
prior close
₹4930.90
announcement price
After-mkt
timing
Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)+0.5%+3.2% vs market
Pharmaceuticals peers, median of 159sector+0.4%+3.3% vs sector

On the reaction day the stock moved 3.2 pts more than Nifty Smallcap 250 and 3.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
+3.2
10m
+4.5
15m
+4.1
30m
+5.8
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
+3.7+0.5+3.2+0.4+3.3
Next day
+8.8+0.6+8.2+0.2+8.6
2d
+7.4-0.1+7.5-0.0+7.4
3d
+5.6-1.7+7.3-1.2+6.8
4d
+5.2-1.8+7.0-1.8+7.0
5d
+5.4-1.0+6.4-1.8+7.2
1w
+4.7-1.7+6.5-2.6+7.3
15d
+1.5-6.3+7.7-7.0+8.5
1m
+0.6-5.4+6.0-5.1+5.7
2m
+1.9-3.2+5.1-3.5+5.5
3m
+2.3+6.1-3.7+3.2-0.9
UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 159Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Pfizer posted Q3 FY26 revenue of 645 crore, up 20% YoY. Net profit rose 11% to 142 crore. For 9M FY26, revenue grew 12% to 1,890 crore and PAT rose 20% to 523 crore. The company recorded 58 crore in exceptional items, including 40 crore in personnel separation costs from a Cipla supply and marketing deal for four brands, and 19 crore impact from new Labour Codes. Limited review report by B S R and Co. LLP is clean with no modifications.

Likely market impact

Near 20% revenue growth and 11% PAT rise in Q3 are positive. Exceptional charge of 58 cr from Cipla deal and Labour Codes weighs on earnings.